Infectious Diseases Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
BMC Pulm Med. 2022 Feb 11;22(1):60. doi: 10.1186/s12890-022-01853-y.
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia of unknown aetiology with a mean survival rate of less than 3 years. No previous studies have been performed on the role of co-infection (viral and bacterial infection) in the pathogenesis and progression of IPF. In this study, we investigated the role of viral/bacterial infection and coinfection and their possible association with pathogenesis and progression of IPF.
We investigated the prevalence and impact of bacterial and viral coinfection in IPF patients (n = 67) in the context of pulmonary function (FVC, FEV and DL), disease status and mortality risk. Using principal component analysis (PCA), we also investigated the relationship between distribution of bacterial and viral co-infection in the IPF cohort.
Of the 67 samples, 17.9% samples were positive for viral infection, 10.4% samples were positive for bacterial infection and 59.7% samples were positive coinfection. We demonstrated that IPF patients who were co-infected had a significantly increased risk of mortality compared (p = 0.031) with IPF patients who were non-infected [Hazard ratio: 8.12; 95% CI 1.3-26.9].
In this study, we report for the first time that IPF patients who were coinfected with bacterial and viral infection have significantly decreased FVC and DL (% predicted). Besides, the results demonstrated the increased AE-IPF, increased incidence of death and risk of mortality in infected/coinfected patients compared to non-infected IPF patients.
特发性肺纤维化(IPF)是一种病因不明的进行性间质性肺炎,平均生存率不足 3 年。以前没有研究过病毒和细菌合并感染(co-infection)在 IPF 的发病机制和进展中的作用。在这项研究中,我们研究了病毒/细菌合并感染的作用及其与 IPF 发病机制和进展的可能关联。
我们在肺功能(FVC、FEV 和 DL)、疾病状况和死亡风险的背景下,研究了 IPF 患者(n=67)中细菌和病毒合并感染的流行率和影响。我们还使用主成分分析(PCA)研究了 IPF 队列中细菌和病毒合并感染的分布之间的关系。
在 67 个样本中,17.9%的样本检测到病毒感染阳性,10.4%的样本检测到细菌感染阳性,59.7%的样本检测到合并感染阳性。我们表明,与未感染的 IPF 患者相比,合并感染的 IPF 患者的死亡风险显著增加(p=0.031)[风险比:8.12;95%置信区间 1.3-26.9]。
在这项研究中,我们首次报告 IPF 患者合并细菌和病毒感染与 FVC 和 DL(%预测)显著降低有关。此外,结果表明,与未感染的 IPF 患者相比,感染/合并感染患者的 AE-IPF 增加、死亡发生率增加和死亡风险增加。